Advanced search
Publication Cover
Expert Review of Ophthalmology Volume 7, 2012 - Issue 5
Submit an article Journal homepage
26
Views
1
CrossRef citations to date
0
Altmetric
Drug Profile

Tafluprost in the treatment of glaucoma

Kevin Kaplowitz University Hospital Medical Center, SUNY Stony Brook, NY, USA. [email protected]; University Hospital Medical Center, SUNY Stony Brook, NY, USA. [email protected]; University Hospital Medical Center, SUNY Stony Brook, NY, USA. [email protected]
&
James C Tsai Department of Ophthalmology and Visual Science, Yale University School of Medicine Chief of Ophthalmology Yale-New Haven Hospital New Haven, CT, USA; Department of Ophthalmology and Visual Science, Yale University School of Medicine Chief of Ophthalmology Yale-New Haven Hospital New Haven, CT, USA
Pages 401-407 | Published online: 09 Jan 2014

References

  • Quigley HA. Glaucoma. Lancet 377(9774), 1367–1377 (2011).
  • Kass MA, Heuer DK, Higginbotham EJ et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120(6), 701–713 (2002).
  • Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 120(10), 1268–1279 (2002).
  • Group CN-TGS. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am. J. Ophthalmol. 126(4), 487–497 (1998).
  • Allingham RR, Shields MB. Shields’ Textbook Of Glaucoma. Lippincott Willliams & Wilkins, PA, USA, (2011).
  • Nordmann JP, Mertz B, Yannoulis NC, Schwenninger C, Kapik B, Shams N; Unoprostone Monotherapy Study Group-EU. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data. Am. J. Ophthalmol. 133(1), 1–10 (2002).
  • Ishida N, Odani-Kawabata N, Shimazaki A, Hara H. Prostanoids in the therapy of glaucoma. Cardiovasc. Drug Rev. 24(1), 1–10 (2006).
  • Cheng JW, Cai JP, Li Y, Wei RL. A meta-analysis of topical prostaglandin analogs in the treatment of chronic angle-closure glaucoma. J. Glaucoma 18(9), 652–657 (2009).
  • van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 112(7), 1177–1185 (2005).
  • Stamer WD, Huang Y, Seftor RE, Svensson SS, Snyder RW, Regan JW. Cultured human trabecular meshwork cells express functional α 2A adrenergic receptors. Invest. Ophthalmol. Vis. Sci. 37(12), 2426–2433 (1996).
  • Einarson TR, Kulin NA, Tingey D, Iskedjian M. Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma. Clin. Ther. 22(12), 1502–1515 (2000).
  • David R. Changing therapeutic paradigms in glaucoma management. Expert Opin. Investig. Drugs 7(7), 1063–1086 (1998).
  • Camras CB, Alm A. Initial clinical studies with prostaglandins and their analogues. Surv. Ophthalmol. 41(Suppl. 2), S61–S68 (1997).
  • Pozarowska D. Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension. Clin. Ophthalmol. 4, 1229–1236 (2010).
  • Nakajima T, Matsugi T, Goto W et al. New fluoroprostaglandin F(2α) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol. Pharm. Bull. 26(12), 1691–1695 (2003).
  • Takagi Y, Nakajima T, Shimazaki A et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP-receptor agonist, as an ocular hypotensive drug. Exp. Eye Res. 78(4), 767–776 (2004).
  • Camras CB, Bito LZ. Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied prostaglandin F2α. Curr. Eye Res. 1(4), 205–209 (1981).
  • Crawford K, Kaufman PL. Pilocarpine antagonizes prostaglandin F2α-induced ocular hypotension in monkeys. Evidence for enhancement of uveoscleral outflow by prostaglandin F2α. Arch. Ophthalmol. 105(8), 1112–1116 (1987).
  • Nilsson SF, Samuelsson M, Bill A, Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2α-1-isopropylester in the cynomolgus monkey. Exp. Eye Res. 48(5), 707–716 (1989).
  • Stjernschantz JW. From PGF(2α)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture. Invest. Ophthalmol. Vis. Sci. 42(6), 1134–1145 (2001).
  • Akaishi T, Kurashima H, Odani-Kawabata N, Ishida N, Nakamura M. Effects of repeated administrations of tafluprost, latanoprost, and travoprost on optic nerve head blood flow in conscious normal rabbits. J. Ocul. Pharmacol. Ther. 26(2), 181–186 (2010).
  • Mayama C, Ishii K, Saeki T, Ota T, Tomidokoro A, Araie M. Effects of topical phenylephrine and tafluprost on optic nerve head circulation in monkeys with unilateral experimental glaucoma. Invest. Ophthalmol. Vis. Sci. 51(8), 4117–4124 (2010).
  • Dong Y, Watabe H, Su G, Ishikawa H, Sato N, Yoshitomi T. Relaxing effect and mechanism of tafluprost on isolated rabbit ciliary arteries. Exp. Eye Res. 87(3), 251–256 (2008).
  • Kurashima H, Watabe H, Sato N, Abe S, Ishida N, Yoshitomi T. Effects of prostaglandin F(2a) analogues on endothelin-1-induced impairment of rabbit ocular blood flow: comparison among tafluprost, travoprost, and latanoprost. Exp. Eye Res. 91(6), 853–859 (2010).
  • Fukano Y, Kawazu K. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats. Drug Metab. Dispos. 37(8), 1622–1634 (2009).
  • Uusitalo H, Kaarniranta K, Ropo A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol. Suppl. (Oxf.) 242, 7–13 (2008).
  • Burstein NL. Preservative alteration of corneal permeability in humans and rabbits. Invest. Ophthalmol. Vis. Sci. 25(12), 1453–1457 (1984).
  • Pellinen P, Lokkila J. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost. Ophthalmic Res. 41(2), 118–122 (2009).
  • Januleviciene I, Derkac I, Grybauskiene L, Paulauskaite R, Gromnickaite R, Kuzmiene L. Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma. Clin. Ophthalmol. 6, 103–109 (2012).
  • Ota T, Murata H, Sugimoto E, Aihara M, Araie M. Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation. Invest. Ophthalmol. Vis. Sci. 46(6), 2006–2011 (2005).
  • Kurashima H, Asai Y, Aihara M, Ishida N, Nakamura M, Araie M. Ocular hypotensive effect of tafluprost in latanoprost low-responder cynomolgus monkeys. J. Glaucoma 21(2), 123–128 (2012).
  • Thygesen J. In search of improved prostaglandin treatment for glaucoma. Acta Ophthalmol. Suppl. (Oxf.) 242, 5–6 (2008).
  • Sutton A, Gilvarry A, Ropo A. A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males. J. Ocul. Pharmacol. Ther. 23(4), 359–365 (2007).
  • Sutton A, Gouws P, Ropo A. Tafluprost, a new potent prostanoid receptor agonist: a dose-response study on pharmacodynamics and tolerability in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 46(8), 400–406 (2008).
  • Traverso CE, Ropo A, Papadia M, Uusitalo H. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost. J. Ocul. Pharmacol. Ther. 26(1), 97–104 (2010).
  • Uusitalo H, Pillunat LE, Ropo A; Phase III Study Investigators. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked Phase III study. Acta Ophthalmol. 88(1), 12–19 (2010).
  • Chabi A, Varma R, Tsai JC et al. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 153(6), 1187–1196 (2012).
  • Hamacher T, Airaksinen J, Saarela V, Liinamaa MJ, Richter U, Ropo A. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol. Suppl. (Oxf.) 242, 14–19 (2008).
  • Aihara M. Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Clin. Ophthalmol. 4, 163–170 (2010).
  • Milla E, Stirbu O, Rey A et al. Spanish multicenter tafluprost tolerability study. Br. J. Ophthalmol. 96(6), 826–831 (2012).
  • Hommer A, Mohammed Ramez O, Burchert M, Kimmich F. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. Curr. Med. Res. Opin. 26(8), 1905–1913 (2010).
  • Schnober D, Hofmann G, Maier H, Scherzer ML, Ogundele AB, Jasek MC. Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension. Clin. Ophthalmol. 4, 1459–1463 (2010).
  • Mochizuki H, Itakura H, Yokoyama T, Takamatsu M, Kiuchi Y. Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects. Jpn. J. Ophthalmol. 54(4), 286–290 (2010).
  • Erb C, Lanzl I, Seidova SF, Kimmich F. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension. Adv. Ther. 28(7), 575–585 (2011).
  • Nakano T, Yoshikawa K, Kimura T, Suzumura H, Nanno M, Noro T. Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less. Jpn. J. Ophthalmol. 55(6), 605–613 (2011).
  • Stewart WC, Garrison PM. β-blocker-induced complications and the patient with glaucoma. Newer treatments to help reduce systemic adverse events. Arch. Intern. Med. 158(3), 221–226 (1998).
  • Park J, Cho HK, Moon JI. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn. J. Ophthalmol. 55(1), 22–27 (2011).
  • Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. Periorbital changes associated with topical bimatoprost. Ophthal. Plast. Reconstr. Surg. 24(4), 302–307 (2008).
  • Choi HY, Lee JE, Lee JW, Park HJ, Lee JE, Jung JH. In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytes. J. Ocul. Pharmacol. Ther. 28(2), 146–152 (2012).
  • Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv. Ophthalmol. 47(Suppl. 1), S219 (2002).
  • Markomichelakis NN, Kostakou A, Halkiadakis I, Chalkidou S, Papakonstantinou D, Georgopoulos G. Efficacy and safety of latanoprost in eyes with uveitic glaucoma. Graefes Arch. Clin. Exp. Ophthalmol. 247(6), 775–780 (2009).
  • Liang H, Pauly A, Riancho L, Baudouin C, Brignole-Baudouin F. Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system. Br. J. Ophthalmol. 95(6), 869–875 (2011).
  • Hommer A, Kimmich F. Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost. Clin. Ophthalmol. 5, 623–631 (2011).
  • Kass MA, Gordon M, Morley RE Jr, Meltzer DW, Goldberg JJ. Compliance with topical timolol treatment. Am. J. Ophthalmol. 103(2), 188–193 (1987).
  • Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J. Glaucoma 12(5), 393–398 (2003).
  • Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative-free glaucoma medication. Br. J. Ophthalmol. 86(4), 418–423 (2002).
  • Rao VP, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs 21(3), 167–177 (2007).
  • Stamer WD, Acott TS. Current understanding of conventional outflow dysfunction in glaucoma. Curr. Opin. Ophthalmol. 23(2), 135–143 (2012).
  • Tanihara H, Inatani M, Honjo M, Tokushige H, Azuma J, Araie M. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch. Ophthalmol. 126(3), 309–315 (2008).
  • Williams RD, Novack GD, van Haarlem T, Kopczynski C; AR-12286 Phase 2A Study Group. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am. J. Ophthalmol. 152(5), 834–841.e1 (2011).
  • Lagrèze WA, Knörle R, Bach M, Feuerstein TJ. Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. Invest. Ophthalmol. Vis. Sci. 39(6), 1063–1066 (1998).
  • Pellegrini JW, Lipton SA. Delayed administration of memantine prevents N-methyl-d-aspartate receptor-mediated neurotoxicity. Ann. Neurol. 33(4), 403–407 (1993).
  • Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol. 87(4), 450–454 (2009).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.